Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.)
Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting.
Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy.
"The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement.
The data, opens new tab were presented at the ASCO meeting that concluded earlier this week.
The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes.
Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months.
The other half of the patients received chemotherapy for 12 months.
The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk.
"It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said.
As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests.
Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use.
But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab.
Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI.
After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding.
That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy.
Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study.
But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed.
Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab.
In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD.
Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness.
The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users.
Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use.
Semaglutide is the active ingredient in the widely used Novo Nordisk (NOVOb.CO), opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's (SASY.PA), opens new tab discontinued Adlyxin.
GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION.
Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect.
At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD.
'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto.
'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.'
(To receive the full newsletter in your inbox for free sign up here)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
a day ago
- Reuters
Magnitude 6 earthquake strikes off coast of Hokkaido, Japan, GFZ says
June 21 (Reuters) - A Magnitude 6 earthquake struck off coast of Hokkaido, Japan on Sunday, the German Research Centre for Geosciences (GFZ) said. The quake was at a depth of 10 km (6.21 miles), GFZ said.
Scottish Sun
2 days ago
- Scottish Sun
Are YOU eligible for free fat jabs on the NHS? As GPs start dishing out Mounjaro – all you need to know
Our round-up also reveals what you need to do if your GP denies you a fat jab prescription and advice if you're intending on buying them privately NATIONAL JAB SERVICE Are YOU eligible for free fat jabs on the NHS? As GPs start dishing out Mounjaro – all you need to know THEY are arguably the biggest medical breakthrough of recent times. And from Monday, so-called 'fat jabs' will be made available to many more Brits on the NHS. Advertisement 5 From Monday, GPs will begin prescribing the weight-loss jab Mounjaro in the first anti-obesity rollout of its kind Credit: Getty 5 Health chiefs hope the Mounjaro rollout will turn the tide on England's obesity crisis Credit: Getty In what marks the dawn of a new era, GPs will begin prescribing the weight-loss jab Mounjaro in the first anti-obesity rollout of its kind. More than three million people are thought to be eligible for tirzepatide - the active drug in Mounjaro - the strongest jab on the market. Health chiefs hope it will turn the tide on England's obesity crisis which has seen rates double since the 1990s. Advertisement Injections including Ozempic and Wegovy have previously only been available for type 2 diabetes or through specialist slimming clinics. Family doctors will now be encouraged to prescribe them in a bid to get more people on the meds. Experts hope widespread use will slash work sick days and boost the economy, while reducing rates of cancer, heart disease and dementia. But demand for the drugs is already huge and NHS clinics cannot dish them out fast enough. Here is everything you need to know as the rollout begins: Advertisement What is Mounjaro and what has it been used for so far? 5 Studies found Mounjaro caused 20 per cent weight loss over 18 months Credit: Reuters FOR anyone who has missed the frenzy, Mounjaro, aka tirzepatide, is the newest weight loss injection used on the NHS. It has been around since 2022 and triggers fullness hormones in the gut to prevent hunger and over-eating. This works the same as older jabs Wegovy and Ozempic, all known as GLP-1 agonists, but a recent trial showed it is more effective. A head-to-head study in the New England Journal of Medicine found Mounjaro caused 20 per cent weight loss over 18 months, while semaglutide – the active ingredient in Wegovy and Ozempic – led to 14 per cent. Advertisement All the jabs were originally invented to treat type 2 diabetes but trials found they could also cause major weight loss. Pharma firms have cashed in on the discovery and UK prescriptions have skyrocketed. NHS prescriptions of Mounjaro in England surged from just 3,300 in 2023 to 1.1million last year, and more than a million people are estimated to be buying it online. Weight Loss Jabs - Pros vs Cons Who will be eligible in the new rollout? THE new rollout starting on Monday will allow GPs to prescribe tirzepatide for weight loss, starting with those patients whose weight places them at greatest health risk. Top of the list will be those with a body mass index (BMI) of 40 or higher and four weight-related health conditions. Advertisement A BMI of 40 is roughly equal to weighing 16st (102kg) for an average height 5'3' woman, or 19st 6lbs (123kg) for an average 5'9' man. Weight-related conditions include high cholesterol, high blood pressure, prediabetes, type 2 diabetes, obstructive sleep apnoea and heart disease. Patients will likely be expected to have tried diet and exercise first before being offered a jab. Many are likely to miss out, as some 13.5million adults in England are obese but only 3.4million are estimated to be eligible in the rollout. How will the rollout be run and what is new? 5 Wes Streeting wants a more widespread use of the drugs but patients must also receive check-ups Credit: Getty Advertisement WHAT'S new is that the rollout will be the first run by NHS primary care, led by GP surgeries. In theory this should make life easier for patients – but GPs will not be able to meet the huge demand. NHS bosses have admitted it will take a staggering 12 years to treat everyone who is eligible. Just 220,000 extra people are likely to get Mounjaro by 2028. Private prescriptions, costing about £100-£150 per month, already vastly outnumber that and are rising. Advertisement Health Secretary Wes Streeting wants a faster rollout and more widespread use of the drugs but patients must also receive regular check-ups and lifestyle help. Officials are investigating whether they can dish them out through pharmacies or the NHS app to take a load off GPs. Professor Jason Halford, of the European Association for the Study of Obesity, said: 'These drugs have the potential to help millions. 'If the government and NHS are serious about prevention they need to reconsider their position on the speed of the rollout of these drugs.' Professor John Deanfield, a heart doctor at University College London, added: 'These drugs provide a real opportunity to delay many diseases of ageing all at the same time and potentially transform society. Advertisement 'I hope it won't take 10 years to do something that is so needed.' What if my GP says no? 5 If you are eligible but your GP denies you a prescription, you may be able to ask for a referral to specialist weight management services Credit: Getty MANY people are expected to miss out and some surgeries are already pouring cold water on patients' hopes. Fairhill Medical Practice in Kingston upon Thames said: 'Once we are able to prescribe weight loss injections they will be offered to those with the highest medical need only, which may mean that a lot of patients will be disappointed.' Millions who meet the prescription criteria will simply have to be denied the drugs because doctors are so busy. Advertisement On top of everything else England's 6,300 doctors' surgeries have to deal with, they do not have the capacity to offer the necessary long-term supervision for millions more people at once. Experts reckon private prescriptions will rocket even more as frustrated patients give up waiting. If you are eligible but your GP denies you a prescription, you may be able to ask for a referral to specialist weight management services. Known as tier 2 and tier 3 weight management services, they may prescribe the jabs after other weight loss attempts. Many people are expected to find it easier to go private, with the injections widely available from high street pharmacies like Boots, Superdrug, and even Asda. Advertisement Olivier Picard, of the National Pharmacy Association, said: 'NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately.' Advice for people buying them privately BUYING the drugs online might seem like the faster fix – but buyer beware. Slimming success stories are everywhere but so, too, are tales of horror. Many patients have been duped by dodgy sellers, suffered severe side effects or even died after taking jabs they bought online. Bargain prices, easy tick-box applications, or prescriptions with no follow-up, should all be red flags to online shoppers. Advertisement Many pharmacies have been rapped for giving them away to people who do not meet the obesity criteria, potentially putting their health at risk. Dose strength is partly based on size and pretending you are fatter than you are could mean you end up with a medication too strong for your body, raising the risk of serious side effects. The most common side effects from the injections include feeling sick, vomiting, diarrhoea or other gut troubles. If not treated properly people can suffer more serious impacts like dehydration, gallstones, pancreatitis or allergic reactions – and more than 100 deaths in the UK have so far been linked to the jabs. The General Pharmaceutical Council issued new rules in February to say that all pharmacies must verify a patient's height and weight, and conduct at least a video call – if not face-to-face appointment – before prescribing weight loss injections. Advertisement Dr Emily Pegg, associate vice president at Lilly, which makes Mounjaro, said: 'This is still a prescription-only medicine, should only be prescribed by a registered healthcare professional and needs to be dispensed by a registered pharmacy. 'It is not something that people should be able to buy by just going out and going on to a social media site and clicking a button and it gets delivered to them. 'That is not appropriate and is probably illegal. 'Patient safety is a high priority.' Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Future of fat jabs WHILE the Mounjaro rollout is expected to kick off with a whimper and not a bang, it is hoped it will mark the beginning of a new era in weight loss medicine. Advertisement Brits have been getting gradually fatter for decades and no medication or government policy has managed to beat the bulge. The drugs appear super-effective, reasonably priced and relatively safe, and could help millions slim down after failed diets. They are expected to reduce the risks of type 2 diabetes, cancer and dementia. And studies increasingly show they improve health in other ways on top of weight loss, too, reducing the risk of heart attacks and strokes. NHS medical director, Professor Sir Stephen Powis, believes they could one day be as transformative as cholesterol-lowering statins, which have slashed heart attacks since they were rolled out decades ago. Advertisement Prof Powis said: 'I think over time it's highly likely that these drugs will become more widespread. 'I think there will be a combination of increased evidence of positive outcomes and costs dropping, and we will learn better how to deploy them. 'This is very exciting – we're in the foothills of learning how to use them.'
Daily Mail
2 days ago
- Daily Mail
EXCLUSIVE I nearly DIED after developing toxic shock syndrome... here are the symptoms I overlooked
At only 15, Shannon Turner suffered a near-deadly case of toxic shock syndrome, which was so severe she was given a 50 percent chance of survival - all from using a tampon. Now, she has laid bare the horrifying ordeal exclusively with the Daily Mail. 'It put me in a coma and nearly took my life - I hadn't even had my period for a full year yet,' Shannon, who was on a family vacation at the time, explained. Shannon revealed she began to feel ill in the evening after she landed, but she assumed it was just jet lag and tried to sleep it off. But she woke up the next day with extreme symptoms, including: vomiting, diarrhea, a fever, and fatigue. 'I was brought to the doctor that afternoon, given a shot for nausea, and sent home,' she continued. 'I continued to deteriorate and was brought back to the doctor later that same day.' 'My last memory is collapsing in the office and laying on the ground because it hurt too much to sit up,' she recalled. 'My heart rate was extremely high, my blood pressure was dangerously low, and I was rushed to the ICU. I didn't wake up until a few days later.' Toxic Shock Syndrome is a 'rare complication of certain types of bacterial infections,' according to MayoClinic. 'It can be fatal. 'Risk factors for toxic shock syndrome include skin wounds, surgery, and the use of tampons and other devices, such as menstrual cups and birth control sponges or diaphragms.' While Shannon was unconscious, doctors worked furiously to diagnose her - initially misdiagnosing her with meningitis and nearly performed an unnecessary spinal tap. 'Thankfully, my mom mentioned to a family member that I was on my period - and that's when menstrual toxic shock syndrome (mTSS) was suggested,' she shared. 'The doctors were informed and my treatment plan shifted. I was incredibly lucky the infectious disease doctor on call had studied toxic shock and knew exactly what to do, but because mTSS progresses so quickly, I was still given a 50/50 chance of survival.' She explained that after the doctors saved her life, she was sent home with 'little guidance' on what to expect during recovery, or how long her symptoms would last - and the aftermath was brutal. 'My hospital stay was only a few days, but the recovery afterward took much longer,' Shannon said. 'I dealt with memory loss, anxiety, attention issues, and depression. My periods also became extremely painful. 'From the age of 15, I was put on prescription painkillers to manage my menstrual pain.' Her experience led to her starting her nonprofit, Protect Her Inc., which is dedicated to 'revolutionizing menstrual health education.' 'We believe knowledge is power - and yet, so many people are navigating their cycles with almost none,' she pointed out. 'I began to see why [there were no recourses], because periods have been taboo for far too long. It's the same reason I never talked about my experience with mTSS, and that silence was incredibly isolating.' Now, over 15 years later, Shannon regularly shares tips on how to avoid the life-threatening situation happening to other people - as well as the symptoms she ignored. 'My message to anyone using tampons is: use the lowest absorbency possible. Your tampon should be saturated when you remove it - if your flow is light, opt for a liner instead,' she listed. She also advises against using tampons overnight, noting if you begin to get sick you won't notice the symptoms if you're asleep. 'We need to stay aware of what our bodies are telling us - especially when there's a foreign object inside us,' she pointed out. Shannon added it's important to learn about the brands of sanitary products you're using, and make sure you're comfortable with their ingredients and manufacturing standards. 'Most importantly, be in tune with your body. It's always communicating with us, if we take the time to listen,' she urged. Shannon also advises people to immediately take a tampon out if they start feeling sick - describing the symptoms as flu-like. 'So [if you experience] headaches, nausea, vomiting, diarrhea, fever - take the tampon out,' she insisted. 'If you feel even worse go seek medical attention.' Shannon now hopes to educate young women through her non-profit, Protect Her Inc, which provides comprehensive menstrual education to adolescents aged seven to 18, with 'a focus on practical knowledge that fosters confidence, health literacy, and open dialogue.' According to National Library of Medicine, studies have shown the risk of mTSS was higher in young women who used tampons, than in women who used menstrual pads. They noted everyone should be aware of the symptoms of mTSS, which are early flu-like symptoms near or during menstruation, including acute onset of fever, vomiting and diarrhea, and progressive dizziness upon standing, and said people should should seek immediate medical attention if experiencing these symptoms.
